The TREOCAPA randomized clinical trial demonstrates that while prophylactic intravenous acetaminophen effectively promotes patent ductus arteriosus closure in extremely preterm infants, it does not significantly increase survival without severe neonatal morbidities at 36 weeks' postmenstrual age.